Pharming Group N.V. (PHAR) Stock

Pharming Group N.V. - ADR is the American Depositary Receipt for shares of Pharming Group N.V., a global biopharmaceutical company headquartered in Leiden, Netherlands, and founded in 1988. The company focuses on commercializing and developing innovative medicines, including protein replacement therapies and precision medicines, to treat rare, debilitating, and life-threatening diseases. Its lead products include RUCONEST, a recombinant C1 esterase inhibitor for treating acute hereditary angioedema attacks in adult and adolescent patients, and Joenja (leniolisib), an oral small molecule PI3K delta inhibitor approved for activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. - ADR also advances a pipeline featuring OTL-105, an investigational gene therapy for hereditary angioedema, and KL1333 for primary mitochondrial disease, alongside Phase II programs expanding Joenja into primary immunodeficiencies and common variable immunodeficiency. Operating in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific, the company employs specialized bioprocessing and maintains collaborations for research, development, manufacturing, and commercialization to address unmet needs in rare diseases.